Resurge Therapeutics Presents Clinical Results on Its Intraprostatic Drug Elution (IPDE) Platform for Benign Prostatic Hyperplasia (BPH) at AUA 2026

Why It Matters

The data suggest a minimally invasive, localized drug‑delivery option that could cut reliance on chronic medication or surgery for BPH, potentially reshaping urologic care and market dynamics.

Key Takeaways

• IPDE cut IPSS by 15 points in both studies.
• Qmax increased ~4 mL/s after one year (transperineal) and 4.1 mL/s (transrectal).
• Transrectal arm showed 23% prostate volume reduction at six months.
• 80% of transperineal patients reported clinically meaningful benefit.
• Resurge to launch larger global placebo‑controlled trials.

Pulse Analysis

Benign prostatic hyperplasia remains one of the most prevalent urologic conditions in aging men, driving a market dominated by daily alpha‑blockers, 5‑alpha‑reductase inhibitors, and invasive procedures such as transurethral resection. While effective, chronic drug regimens can cause systemic side effects, and surgery carries procedural risks and recovery time. The industry has long sought a middle ground: a therapy that delivers potent agents directly to the prostate, minimizing systemic exposure while avoiding the invasiveness of surgery.

Resurge Therapeutics’ intraprostatic drug elution (IPDE) platform addresses that gap by implanting bioabsorbable, paclitaxel‑eluting devices via transperineal or transrectal routes. The early‑phase data reveal a robust 15‑point drop in International Prostate Symptom Score and a roughly 4 mL/s increase in peak urinary flow, outcomes comparable to or exceeding many pharmacologic regimens. Notably, the transrectal arm achieved these gains within a month and demonstrated a 23% reduction in prostate volume at six months, hinting at a disease‑modifying effect rather than mere symptom control.

Looking ahead, Resurge’s commitment to larger, placebo‑controlled trials positions the IPDE platform for potential FDA review and broader adoption. If subsequent studies confirm durability and safety, the technology could carve out a new therapeutic niche, attracting urologists seeking a one‑time, office‑based solution. Such a shift would have ripple effects across pharmaceutical sales, device manufacturers, and payer reimbursement models, underscoring the strategic importance of localized drug delivery in the evolving BPH landscape.